Archives

Shahin Gharakhanian MD Consulting LLC, 2022 Mid-Year Report:

Selected Projects listed in alphabetical order: [ACTICOR-BIOTECH, Paris, France] US Medical Executive for Acticor BiotechDeveloping Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.ACTISAVE phase II/III Study [(NCT05070260] ongoing.Please refer to : www.acticor-biotech.com [DECOY...

Continue reading »

[Sept 2021] Presentation @ Vaccine (Virtual) Summit 2021

Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray. Barbara Hibner*, Peter Marschel*, Frederick E. Pierce II*, Shahin Gharakhanian** *Research & Development Program Team, **Scientific Advisory Board, DECOY Therapeutics, CAMBRIDGE MA, USA. [Contact:...

Continue reading »

Shahin Gharakhanian MD 1H2021 COVID-19 Activities’ PROGRESS REPORT

* Utay, N. S., Asmuth, D. M, Gharakhanian, S., Contreras, M., Warner, C. D., & Detzel, C. J. (2021). Potential use of serum-derived bovine immunoglobulin/protein isolate for the management ofCOVID-19. Drug Development Research, 1–7. https://doi.org/10.1002/ddr.21841 * GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind,...

Continue reading »

Shahin Gharakhanian MD 2020 COVID-19 Activities’ REPORT

On 30 December 2019 a ProMed email from the International Society of Infectious Diseases (IDSA) contained information on <Undiagnosed pneumonia in China>, thus alerting the world to what was to become the worst health crisis in 100 years. On 24 January 2020, the New England Journal of Medicine (2020, 382: 727-733) published a brief report from...

Continue reading »

4th Boston Biotechnology Virtual Summit

www.bostonbiotechnologysummit.com The 4th Boston ● Paris Biotechnology Virtual Summit ● Focus on Covid-19 – will be held, via a zoom platform, on Thursday 15 October 2020, 11 AM – 01 PM US EDT [17:00 – 19:00 EU CET] in three sequential panels as below. The Program Committee, listed below*, have convened renowned experts...

Continue reading »

Stroke is the Second Cause of Mortality Worldwide: ACTICOR-BIOTECH Expands ACTIMIS Stroke Study to the UNITED STATES — Shahin Gharakhanian MD Consulting LLC Leads Nationwide Project from Cambridge MA

Cambridge MA, 02.03.2020. Stroke is listed as the 2nd cause of mortality worldwide according to the World Health Organization. ACTICOR-BIOTECH [CEO: Dr Gilles AVENARD], a leading, fully-funded, PARIS-based, biotechnology company is assessing its novel agent ACT017 as an add on therapy to Standard of Care in AIS: Acute Ischemic Stroke. This year Acticor-Biotech...

Continue reading »